Page 1587 - Small Animal Internal Medicine, 6th Edition

Index 1559

Gastric outflow obstruction/gastric stasis Generalized lymphadenopathy, 1314f, Glucocorticoid(s), 441. see also Granulocytotropic anaplasmosis
(Continued) 1417 Corticosteroid(s); specific drug canine, 1469–1471
gastric antral mucosal hypertrophy Genetic variability screening, 936b acute addisonian crisis treated with, Granulomatous
feline, 1471–1472, 1472f
VetBooks.ir gastric dilation/volvulus, 467–468, Gentamicin, 1437t–1438t adverse effects of, 1223, 1223f meningoencephalomyelitis, 1064,
and, 465, 466f
Genital tract zoonoses, 1542–1543
886–887, 887b
Geriatric canine vestibular disease,
1087–1088, 1120–1121
aspiration pneumonia treated with,
468f
gastric foreign objects in, 466–467
348
1113–1114, 1113f
Granulomatous ulcerative colitis, 495
iatrogenic, 467 Gestation, 949. see also Pregnancy canine chronic bronchitis treated with, Granulomatous splenitis, 1412t
idiopathic gastric hypomotility in, Gestational age, 950–951, 951f, 951b 331–332 Granulosa-theca cell tumors, 954
469–470 Gestational diabetes, 967, 967f chronic hepatitis treated with, 592, Great vessels, 16–17
partial or intermittent chronic gastric Giardia spp., 1533t–1535t, 1538 592f Greyhounds, 1360–1367
volvulus, 469, 469f antigen tests for, 1432 endogenous acid-base balance in, 1362, 1362t
Gastric ulcer, 426f enzyme-linked immunosorbent assays deficiency of, 883 cardiac troponins in, 1363–1364
Gastrin, 424 for detecting, 414 excess of, 1178 clinical chemistry parameters in,
Gastrinomas, 853, 853b fecal flotation for, 1428, 1429f eosinophilic lung disease treated with, 1361–1364
gastrointestinal ulceration/erosion treatment of, 1443 349 clinical pathology in, 1364–1365
from, 470 Giardiasis, 489–490, 489f feline bronchitis treated with, 331 creatinine levels in, 1362
Gastrin-secreting neoplasia, 853–854, Giemsa stain, 1258 gastrointestinal ulceration/erosion dog erythrocyte antigen in, 1360–1361
853b Gingiva, 448t from, 470 electrolytes in, 1362, 1362t
Gastritis, 462–465 Gingivitis granulomatous meningoencephalitis erosive polyarthritis in, 1208, 1245t
acute, 462 description of, 450 treated with, 1121, 1121b erythrocytes in, 1360–1361
atrophic, 463 feline lymphocytic-plasmacytic, hemolysis treated with, 1235–1236 hematology in, 1360–1361, 1365t
canine eosinophilic, 463 450–451 immune-mediated disorders treated hemostasis in, 1361, 1366t
chronic, 463–464 Glipizide, 835 with, 1221–1223, 1222t hypoglobulinemia in, 1362–1363
Helicobacter-associated disease, 464, Glomerular disease, 675–685 immune-mediated hemolytic anemia leukocytes in, 1361
464f clinical findings of, 680–681 treated with, 1235–1236 liver enzymes in, 1362
hemorrhagic gastroenteritis and, complications of, 684–685 immune-mediated polyarthritis platelets in, 1361, 1395
462–463 history-taking, 680 treated with, 1203–1204, 1204t, protein levels in, 1362–1363
lymphocytic-plasmacytic, 463 hyperlipidemia in, 685 1204b serum chemistry reference intervals
Gastroduodenal ulceration and erosion, hypertension in, 685 insulin-secreting β-cell neoplasia in, 1365, 1366t
397–398 hypoalbuminemia in, 684 treated with, 852 thyroid hormones in, 1363
Gastroduodenoscopy immune injury mechanisms, 677, 678b laryngeal paralysis treated with, 278 Growth fraction, 1269
gastrin-secreting neoplasia laboratory findings of, 680–681, 681b lymphocytic-plasmacytic gastritis Growth hormone
evaluations, 853 management of, 681–684, 682b–683b treated with, 463 anabolic effects of, 749–750
indications for, 426, 426f pathogenesis of, 676–677, 676f–677f masticatory muscle myositis treated catabolic effects of, 749–750
technique for, 426 physical examination of, 680 with, 1175 congenital deficiency of. see Pituitary
Gastroduodenostomy, 472 prognosis of, 685 optic neuritis treated with, 1088 dwarfism
Gastroenteritis progression of, 677–678 pulmonary edema caused by, 382 endocrine disorders treated with,
causes of, 1539 sodium retention in, 684 steroid-responsive meningitis-arteritis 896t–897t
hemorrhagic, 462–463, 1368 thromboembolism in, 684–685 treated with, 1119 excessive secretion of. see Acromegaly
Gastroenterocolitis, 1281 Glomerular filtration rate, 658, 661, 688f, thyroid gland function tests affected pituitary dwarfism treated with,
Gastroesophageal reflux, 455 772 by, 781 755–757
Gastrograms, contrast-enhanced, Glomerular function, diagnostic tests for, Glucocorticoid resistance, 1222 H
422 658–662 Glucosamine, 1197t, 1209t–1210t
Gastrointestinal abnormalities, bladder tumor antigen test, 662 Glucose Haemobartonella canis, 1429–1430
1013–1014 blood urea nitrogen, 658, 659f blood Haemobartonella felis, 1429–1430
Gastrointestinal disorders, 1027–1029, creatinine clearance, 660–661, 661t continuous monitoring systems for, Halitosis, 389–391
1029f–1030f cystatin C, 659 821, 822f causes of, 390b
abdominal distention, 408–411, 410b fibroblast growth factor-23 (FGF-23), for diabetes mellitus monitoring dysphagia and, 389–391
abdominal effusion, 407 659–660 in cats, 835–836, 836–837, Halothane, 49b
abdominal enlargement, 408–411, γ-Glutamyl transferase (GGT), 660 836f Haw syndrome, 1091
410b iohexol clearance, 661 in dogs, 818 Head bobbing, 1106
abdominal pain, 408, 410b kidney injury molecule-1 (KIM-1), measurement of Head tilt, 1109–1116
acute abdomen, 407–408, 408b, 409f 660 in cats, 838f central vestibular disease as cause of,
anorexia, 407, 407b microalbuminuria, 662 methods for, 821 1111f, 1112b. see also Central
clinical manifestations of, 389–411 N-acetyl-β-D-glucosaminidase (NAG), serial curves of, 819–822, 820f–821f, vestibular disease
constipation, 404–405, 404b 660 823f–824f, 837 description of, 1043–1044, 1055–1057
diarrhea. see Diarrhea neutrophil gelatinase-associated stress hyperglycemia effects on, general considerations in, 1109
drooling associated with, 389–391 lipocalin (NGAL), 660 837–839 illustration of, 1044f, 1056f–1058f
drugs used in, 515t–517t radioisotopes, 661 toxicity, 831–832 lesion localization, 1109–1111, 1110b
dysphagia associated with, 389–391 serum creatinine, 658–659 urine, 665 nystagmus, 1109
fecal incontinence, 405 symmetric dimethylarginine, 659 diabetes mellitus monitoring in peripheral vestibular disease as cause
halitosis associated with, 389–391 urine protein-to-creatinine ratio, dogs using, 819 of, 1111f. see also Peripheral
hematemesis. see Hematemesis 661–662 α-Glucosidase inhibitors, 835 vestibular disease
hematochezia, 402, 402b Glomerulonephritis Glucotrol. see Glipizide Head trauma, 1075–1076
hyporexia, 407, 407b clinical features of, 1249 γ-Glutamyl transferase (GGT), 660 Heart
melena, 402–403, 403b diagnosis of, 1248t, 1249–1250 Glutaraldehyde-containing fixatives, 1433 conduction system, 34f
tenesmus, 403–404, 403b etiology of, 1249 Glycolysis, 806–807 infective endocarditis effects on, 134b
vomiting. see Vomiting histopathologic lesions of, 678–679 Glycophorins, 1231 Heart base tumors, 182, 185
weight loss, 405–407, 405b, 406f immune-complex, 676–677, 676f Glycopyrrolate, 97, 386t–388t Heart block
Gastrointestinal ulceration/erosion immune-mediated, 676, 678b, in cats, 90t–91t atrioventricular, 87–88
(GUE), 470–471 1249–1250 in dogs, 90t–91t first-degree, 43–44, 44f
clinical features of, 470 membranoproliferative, 678, 693b dosage of, 90t–91t second-degree, 43–44, 44f
diagnosis of, 470–471, 471f membranous, 678 Glycosuria, 811 third-degree, 43–44, 44f
etiology of, 470 pathogenesis of, 1249b Golden Retriever muscular dystrophy, idiopathic, 87–88
nonsteroidal anti-inflammatory drugs proliferative, 678 1179 Heart disease, signs of, 1
and, 470–471 treatment of, 1249–1250 Gonadotropin-releasing hormone, Heart failure, 1. see also Congestive heart
prognosis of, 471 Glomerulotubular balance, 694–695, 954–955, 1034t–1036t failure
treatment of, 471 695f Gonadotropin-releasing hormone acute therapy for, 65
Gastropexy, 468 Glomerulus agonists, 958 atrioventricular valve disease as cause
Gastrostomy tubes filtration barrier of, 675 Gradual water deprivation, 664 of, 119
enteral feedings using, 436 mesangial cells, 675, 676f Granular casts, 667–668, 667f β-blockers in, 73
esophageal bypass using, 454 structure of, 675, 676f Granulocyte colony-stimulating factor, biventricular, 1
Geigy. see Terbutaline Glossopharyngeal nerve, 1056t, 1280, 1375 cardiac responses to, 55–56
General proprioceptive sensory tracts, 1059–1060 Granulocyte-macrophage colony- causes of, 58–59, 59t
1045 Glucagon, 896t–897t stimulating factor, 1280 characteristics of, 58–59